Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis.

IF 2.7 3区医学 Q3 ONCOLOGY Journal of Cancer Research and Clinical Oncology Pub Date : 2024-09-09 DOI:10.1007/s00432-024-05923-y

Xiansheng Yang, Chang Liu, Zheng Li, Juncai Wen, Jinfu He, Yunxin Lu, Quanxing Liao, Tian Wang, Hongsheng Tang, Xianzi Yang, Lisi Zeng

{"title":"Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis.","authors":"Xiansheng Yang, Chang Liu, Zheng Li, Juncai Wen, Jinfu He, Yunxin Lu, Quanxing Liao, Tian Wang, Hongsheng Tang, Xianzi Yang, Lisi Zeng","doi":"10.1007/s00432-024-05923-y","DOIUrl":null,"url":null,"abstract":"Background: Gastric cancer (GC), a prevalent malignant tumor which is a leading cause of death from malignancy around the world. Peritoneal metastasis accounts for the major cause of mortality in patients with GC. Despite hyperthermia intraperitoneal chemotherapy (HIPEC) improves the therapeutic effect of GC, it's equivocal about the mechanism under HIPEC.Methods: MiR-183-5p expression was sifted from miRNA chip and detected in both GC patients and cell lines by qRT-PCR. Gene interference and rescue experiments were performed to identified biological function in vitro and vivo. Next, we affirmed PPP2CA as targeted of miR-183-5p by dual luciferase reporter assay. Finally, the potential relationship between HIPEC and miR-183-5p was explored.Results: MiR-183-5p is up-regulated in GC and associated with advanced stage and poor prognosis. MiR-183-5p accelerate GC migration in vitro which is influenced by miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin Axis. HIPEC exerts migration inhibition via attenuating miR-183-5p expression.Conclusion: MiR-183-5p can be used as a potential HIPEC biomarker in patients with CC.","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 9","pages":"416"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383839/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-024-05923-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastric cancer (GC), a prevalent malignant tumor which is a leading cause of death from malignancy around the world. Peritoneal metastasis accounts for the major cause of mortality in patients with GC. Despite hyperthermia intraperitoneal chemotherapy (HIPEC) improves the therapeutic effect of GC, it's equivocal about the mechanism under HIPEC.

Methods: MiR-183-5p expression was sifted from miRNA chip and detected in both GC patients and cell lines by qRT-PCR. Gene interference and rescue experiments were performed to identified biological function in vitro and vivo. Next, we affirmed PPP2CA as targeted of miR-183-5p by dual luciferase reporter assay. Finally, the potential relationship between HIPEC and miR-183-5p was explored.

Results: MiR-183-5p is up-regulated in GC and associated with advanced stage and poor prognosis. MiR-183-5p accelerate GC migration in vitro which is influenced by miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin Axis. HIPEC exerts migration inhibition via attenuating miR-183-5p expression.

Conclusion: MiR-183-5p can be used as a potential HIPEC biomarker in patients with CC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

紫杉醇热疗通过 MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin 轴抑制胃癌迁移

背景：胃癌（GC）是一种常见的恶性肿瘤，是全球恶性肿瘤死亡的主要原因。腹膜转移是胃癌患者死亡的主要原因。尽管高热腹腔化疗（HIPEC）能提高GC的治疗效果，但HIPEC的作用机制尚不明确：方法：从miRNA芯片中筛选出MiR-183-5p，并通过qRT-PCR检测其在GC患者和细胞系中的表达。方法：从 miRNA 芯片中筛选出 MiR-183-5p，并通过 qRT-PCR 检测其在 GC 患者和细胞系中的表达。接着，我们通过双荧光素酶报告实验证实了 PPP2CA 是 miR-183-5p 的靶标。最后，我们探讨了HIPEC与miR-183-5p之间的潜在关系：结果：MiR-183-5p在GC中上调，并与晚期和预后不良有关。MiR-183-5p可加速GC的体外迁移，而这一迁移受miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin轴的影响。HIPEC通过降低miR-183-5p的表达抑制迁移：结论：MiR-183-5p可作为CC患者潜在的HIPEC生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cancer Research and Clinical Oncology 医学-肿瘤学

CiteScore

4.00

自引率

2.80%

发文量

577

审稿时长

2 months

期刊介绍： The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.